- Home
- LFVN vs CRDF Comparison
LFVN vs CRDF Comparison
Compare LFVN & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFVN | CRDF |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.2M | 142.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LFVN | CRDF |
|---|---|---|
| Price | $6.22 | $2.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $35.00 | $10.83 |
| AVG Volume (30 Days) | 193.0K | ★ 1.1M |
| Earning Date | 02-04-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | ★ 143.91 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $228,877,000.00 | $501,000.00 |
| Revenue This Year | $1.54 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $7.81 | ★ N/A |
| Revenue Growth | ★ 16.77 | N/A |
| 52 Week Low | $5.69 | $1.90 |
| 52 Week High | $27.38 | $4.99 |
Technical Indicators
Market Signals| Indicator | LFVN | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 62.77 |
| Support Level | $5.80 | $2.61 |
| Resistance Level | $6.41 | $3.31 |
| Average True Range (ATR) | 0.34 | 0.19 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 66.51 | 63.16 |
Price Performance
Historical ComparisonAbout LFVN Lifevantage Corporation (Delaware)
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.